Loading...
CSPC Pharmaceutical Group Limited
CSPCY•PNK
Healthcare
Drug Manufacturers - General
$4.98
$0.03(0.61%)
CSPC Pharmaceutical Group Limited (CSPCY) Financial Performance & Income Statement Overview
Review CSPC Pharmaceutical Group Limited’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
-10.78%
↓ 10.78%
Operating Income Growth
-25.65%
↓ 25.65%
Net Income Growth
-21.59%
↓ 21.59%
Operating Cash Flow Growth
-100.00%
↓ 100.00%
Operating Margin
22.79%
↑ 22.79%
Gross Margin
71.38%
↑ 71.38%
Net Profit Margin
18.72%
↑ 18.72%
ROE
17.55%
↑ 17.55%
ROIC
20.53%
↑ 20.53%
CSPC Pharmaceutical Group Limited (CSPCY) Income Statement & Financial Overview
Review CSPC Pharmaceutical Group Limited's (CSPCY) income statement with detailed quarterly and annual figures.
| Metric | Q2 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|
| Revenue | $16.28B | $15.04B | $7.78B | $8.03B |
| Cost of Revenue | $4.63B | $4.33B | $2.23B | $2.31B |
| Gross Profit | $11.65B | $10.70B | $5.55B | $5.72B |
| Gross Profit Ratio | $0.72 | $0.71 | $0.71 | $0.71 |
| R&D Expenses | $2.54B | $2.47B | $1.37B | $1.30B |
| SG&A Expenses | $5.41B | $4.80B | $2.45B | $2.69B |
| Operating Expenses | $7.95B | $7.27B | $3.77B | $4.02B |
| Total Costs & Expenses | $12.58B | $11.60B | $6.000B | $6.33B |
| Interest Income | $0.00 | $132.15M | $0.00 | $141.15M |
| Interest Expense | $0.00 | $8.17M | $6.16M | $6.29M |
| Depreciation & Amortization | $549.70M | $571.28M | -$39586.00 | $599.69M |
| EBITDA | $4.25B | $4.007B | $1.93B | $1.91B |
| EBITDA Ratio | $0.26 | $0.27 | $0.25 | $0.24 |
| Operating Income | $3.70B | $3.44B | $1.93B | $1.91B |
| Operating Income Ratio | $0.23 | $0.23 | $0.25 | $0.24 |
| Other Income/Expenses (Net) | $98.78M | $2.04B | -$6.16M | $202.38M |
| Income Before Tax | $3.80B | $3.66B | $1.93B | $1.90B |
| Income Before Tax Ratio | $0.23 | $0.24 | $0.25 | $0.24 |
| Income Tax Expense | $749.31M | $678.14M | $341.23M | $311.65M |
| Net Income | $3.02B | $2.84B | $1.53B | $1.54B |
| Net Income Ratio | $0.19 | $0.19 | $0.20 | $0.19 |
| EPS | $0.27 | $0.24 | $0.00 | $0.28 |
| Diluted EPS | $0.27 | $0.24 | $0.00 | $0.28 |
| Weighted Avg Shares Outstanding | $11.84B | $11.85B | $0.00 | $11.89B |
| Weighted Avg Shares Outstanding (Diluted) | $11.84B | $11.85B | $0.00 | $11.89B |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan